Arnaud Chambellan

Arnaud Chambellan

Auto-generated profile, based on publicly available information

Arnaud Chambellan

Hôpital Saint Philibert, Institut Catholique de Lille, Lille, France

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2017 in Respiratory Medicine
Verified
Journal Article
Closed access
TVTrija Vaidya
Trija Vaidya
ACArnaud Chambellan
Arnaud Chambellan
CBClaire De Bisschop
Claire De Bisschop

15 November 2022 in Journal of Asthma
Verified
Journal Article
Closed access
CMC. Menigoz
C. Menigoz
SDS. Dirou
S. Dirou
ACA. Chambellan
A. Chambellan
DHD. Hassoun
D. Hassoun
AMA. Moui
A. Moui
FBFrançois-Xavier Blanc
François-Xavier Blanc
Introduction: Severe eosinophilic asthma (SEA) is associated with multiple exacerbations. Fractional exhaled nitric oxide (FeNO), a biomarker of airway T2 inflammation, is known to be correlated with the risk of exacerbations. While the use of FeNO is well established to predict the therapeutic response to dupilumab (anti-IL-4/IL-13), it remains uncertain for biologics targeting the IL-5 pathway. Methods: We conducted an observational, retrospective, monocentric analysis of adults with SEA who started mepolizumab (anti-IL-5) or benralizumab (anti-IL-5-R) between January 1, 2016 and December 31, 2020. Results: Data were collected for 109 patients. All participants reported uncontrolled asthma with a median of 3 annual exacerbations and a median Asthma Control Test score of 12. They all had an initial blood eosinophilia >300/mm3, with a median at 610/mm3 (IQR 420-856). Patients with a baseline FeNO ≥50 ppb reported more exacerbations in the previous year than those with a FeNO <50 ppb (p = 0.02). After initiation of treatment, change in FeNO was not associated with therapeutic response. However, decrease in the annual number of exacerbations was significantly greater in patients with a baseline FeNO ≥50 ppb than in those with a baseline FeNO <50 ppb (-3.3 ± 2.7 vs -0.9 ± 2.4, respectively; p = 0.01). There was no association between baseline FeNO values and subsequent lung function, asthma control or reduction of oral corticosteroids use. Conclusion: In this real-world cohort, adults with SEA who had a baseline FeNO ≥50 ppb experienced a greater decrease in exacerbations after 12 months of anti-IL-5 or IL-5-R biologics than those with a FeNO <50 ppb.

1 September 2018 in Revue des Maladies Respiratoires
Verified
Journal Article
Closed access
LPLaurent Plantier
Laurent Plantier
NBN. Beydon
N. Beydon
ACA. Chambellan
A. Chambellan
BDB. Degano
B. Degano
CDC. Delclaux
C. Delclaux
BCBruno Chenuel
Bruno Chenuel

1 October 2005 in Neurophysiologie Clinique
Verified
Journal Article
Closed access
CLCaroline Lanctin
Caroline Lanctin
AMArmelle Magot
Armelle Magot
ACArnaud Chambellan
Arnaud Chambellan
STSylvie Nguyen The Tich
Sylvie Nguyen The Tich
YPYann Pereon
Yann Pereon


28 June 2024 in JMIR Research Protocols
Verified
Journal Article
Open access
ABAlec Bass
Alec Bass
SGSarah GEPHINE
Sarah GEPHINE
MMMickaël Martin
Mickaël Martin
MBMarianne Belley
Marianne Belley
MRManon Robic
Manon Robic
FMFrançois Maltais
François Maltais
Background: Pulmonary rehabilitation is widely recommended to improve functional status and as secondary and tertiary prevention in individuals with chronic pulmonary diseases. Unfortunately, access to timely and appropriate rehabilitation remains limited. To help close this inaccessibility gap, telerehabilitation has been proposed. However, exercise testing is necessary for effective and safe exercise prescription. Current gold-standard tests, such as maximal cardiopulmonary exercise testing (CPET) and the 6-minute walk test (6MWT), are poorly adapted to home-based or telerehabilitation settings. This was an obstacle to the continuity of services during the COVID-19 pandemic. It is essential to validate tests adapted to these new realities, such as the 6-minute stepper test (6MST). This test, strongly inspired by 6MWT, consists of taking as many steps as possible on a “stepper” for 6 minutes. Objective: This study aims to evaluate the metrological qualities of 6MST by (1) establishing concurrent validity and agreement between the 6MST and CPET, as well as with the 6MWT; (2) determining test-retest reliability in a home-based setting with direct and remote (videoconferencing) monitoring; and (3) documenting adverse events and participant perspectives when performing the 6MST in home-based settings. Methods: Three centers (Centre de recherche de l’Institut universitaire de cardiologie et de pneumologie de Québec in Québec, Groupement des Hôpitaux de l’Institut Catholique de Lille in France, and FormAction Santé in France) will be involved in this multinational project, which is divided into 2 studies. For study 1 (objective 1), 30 participants (Québec, n=15; France, n=15) will be recruited. Two laboratory visits will be performed to assess anthropometric data, pulmonary function, and the 3 exercise tolerance tests (CPET, 6MWT, and 6MST). Concurrent validity (paired sample t tests and Pearson correlations) and agreement (Bland-Altman plots with 95% agreement limits) will be evaluated. For study 2 (objectives 2 and 3), 52 participants (Québec, n=26; France, n=26) will be recruited. Following a familiarization trial (trial 1), the 6MST will be conducted on 2 separate occasions (trials 2 and 3), once under direct supervision and once under remote supervision, in a randomized order. Paired sample t test, Bland-Altman plots, and intraclass correlations will be used to compare trials 2 and 3. A semistructured interview will be conducted after the third trial to collect participants’ perspectives. Results: Ethical approval was received for this project (October 12, 2023, in Québec and September 25, 2023, in France) and the first participant was recruited in February 2024. Conclusions: This study innovates by validating a new clinical test necessary for the development and implementation of new models of rehabilitation adapted to home and telerehabilitation contexts. This study also aligns with the United Nations Sustainable Development Goals by contributing to augmenting health care service delivery (goal 3) and reducing health care access inequalities (goal 11). Trial Registration: ClinicalTrials.gov NCT06447831; https://clinicaltrials.gov/study/NCT06447831 International Registered Report Identifier (IRRID): DERR1-10.2196/57404